Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 291

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

Open access
Treon, Steven P., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Sheehy, Patricia, Nelson, Marybeth, Willen, Michael, Matous, Jeffrey, Mattern, John, Diener, Jakow G., Keogh, George P., Myers, Thomas J., Boral, Andy, Birner, Ann, Esseltine, Dixie L., Ghobrial, Irene M. · 2009 · Journal of Clinical Oncology

Abstract

Purpose: We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and Methods: A cycle of therapy consisted of bortezomib 1.3 mg/m 2 intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m 2 on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy. Twenty-three patients received a median of seven cycles of treatment. Results: Median bone marrow disease involvement declined from 55% to 10% (P = .0004), serum immunoglobulin M levels declined from 4,830 to 1,115 mg/dL (P < .0001), and hematocrit increased from 29.8% to 38.2% (P = .0002) at best response. The overall response rates and major response rates were 96% and 83% with three complete responses, two near complete responses, three very good partial responses, 11 partial responses, and three minor responses. Responses occurred at a median of 1.4 months. With a median follow-up of 22.8 months, 18 of 23 patients remained free of disease progression. Peripheral neuropathy was the most common toxicity, and it resolved to grade ≤ 1 in 13 of 16 patients at a median of 6.0 months. Four of the first seven treated patients developed herpes zoster, resulting in the institution of prophylactic antiviral therapy. Conclusion: The results demonstrate that BDR produces rapid and durable responses, along with high rates of response and complete remissions in WM. Herpes zoster prophylaxis is necessary with BDR, and reversible peripheral neuropathy was the most common toxicity leading to premature discontinuation of bortezomib in 61% of patients. Exploration of alternative schedules for bortezomib administration that includes weekly dosing should be pursued.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.20.4677

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 291

Metadata

Authors
Treon, S. P., Ioakimidis, L., Soumerai, J. D., Patterson, C. J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., Diener, J. G., Keogh, G. P., Myers, T. J., Boral, A., Birner, A., Esseltine, D. L., & Ghobrial, I. M.
Venue
Journal of Clinical Oncology
Published
2009-08-10
Volume
27
Issue
23
Pages
3830-3835
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2128490833
Cited by
291
References
33
FWCI
8.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. https://app.cochat.ai/papers/10.1200/jco.2008.20.4677
The paper
Treon, S. P., Ioakimidis, L., Soumerai, J. D., Patterson, C. J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., Diener, J. G., Keogh, G. P., Myers, T. J., Boral, A., Birner, A., Esseltine, D. L., & Ghobrial, I. M. (2009). Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.4677

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.